Trireme Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 04-07-2024
- Paid Up Capital ₹ 1.00 Cr
as on 04-07-2024
- Company Age 12 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.00 Cr
as on 04-07-2024
- Revenue 20.00%
(FY 2023)
- Profit 70.93%
(FY 2023)
- Ebitda -6.72%
(FY 2023)
- Net Worth 34.36%
(FY 2023)
- Total Assets 23.24%
(FY 2023)
About Trireme Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹1.00 Cr.
Sahensa Sarkar, Tumpa Sarkar, and Abdul Miah serve as directors at the Company.
- CIN/LLPIN
U85100MP2012PTC029317
- Company No.
029317
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Oct 2012
- Date of AGM
28 Aug 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Bhopal, Madhya Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Trireme Life Sciences Private Limited offer?
Trireme Life Sciences Private Limited offers a wide range of products and services, including Digestive System Drugs & Medicines, Gastrointestinal Drugs, Common Disease Medicines, Pharmaceutical Syrup, Pain Relief Drugs & Pharmaceuticals, Aceclofenac, Allopathic Cough Syrup, Respiratory System Drugs, Anti Asthma Drug, Anti Infective Drugs & Medicines.
Who are the key members and board of directors at Trireme Life Sciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sahensa Sarkar  | Director | 20-Feb-2018 | Current |
| Tumpa Sarkar | Director | 01-Feb-2022 | Current |
| Abdul Miah | Director | 15-May-2018 | Current |
Financial Performance of Trireme Life Sciences.
Trireme Life Sciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 20% increase. The company also saw a substantial improvement in profitability, with a 70.93% increase in profit. The company's net worth Soared by an impressive increase of 34.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Trireme Life Sciences?
In 2023, Trireme Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 13 Apr 2022 | ₹1.00 Cr | Open |
How Many Employees Work at Trireme Life Sciences?
Trireme Life Sciences has a workforce of 3 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Trireme Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Trireme Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
